Dulaglutide
Based on 1 publication(s) in Google Scholar
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 96%
- CAS 番号: 923950-08-7
- 分子量:62561 (Glycosylation, Dominant form)
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Dulaglutide
More
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
WB
-
Others
生物活性
GLP-1 receptor[1]
Dulaglutide (50 nM and 100 nM; 24 h) ameliorates ox-LDL-induced oxidative stress and suppresses ox-LDL-induced mitochondrial dysfunction in human aortic endothelial cells (HAECs)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human aortic endothelial cells (HAECs)
-
Concentration:50 nM, 100 nM
-
Incubation Time:24 hous
-
Result:Suppressed ox-LDL-induced reduction of cell viability and release of lactate dehydrogenase (LDH).
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rats and Transgenic mice[1]
-
Dosage:0, 0.05, 0.5, 1.5, or 5 mg/kg; 0, 0.3, 1, or 3 mg/kg
-
Administration:SC, twice week, for 93 weeks; SC, twice week, for 26 weeks
-
Result:Statistically increased diffuse C-cell hyperplasia and adenomas at ＞0.5 mg/kg.
Decreased Systemic exposures over time in mice.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 923950-08-7
-
性状 Liquid
-
分子量 62561 (Glycosylation, Dominant form)
-
Color Colorless to light yellow
-
別名
LY2189265
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Endocrinol Metab
Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway. [Abstract]2022 Feb;37(1):74-83. PMID: 35144334
Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83. [Abstract]
Dulaglutide (Dula) inhibits palmitic acid (PA)-induced lipid accumulation in HepG2 cells. Cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Lipid accumulation were evaluated using Oil red O staining.
Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83. [Abstract]
Dula glycopeptide (Dula) reduced lipogenesis and triglyceride (TG) synthesis in palmitic acid (PA)-treated HepG2 cells and increased TG secretion. HepG2 cells were pretreated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to analyze the mRNA expression levels of genes encoding sterol regulatory binding protein 1 (SREBP-1), acetyl-CoA carboxylase (ACC), and fatty acid synthase (FAS).
Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83. [Abstract]
Cells were pre-treated with 400 μM PA for 24 hours, followed by treatment with or without 100 nM Dulaglutide and 100 nM exendin (9–39), a GLP-1R antagonist, for 24 hours. FAM3A, GLP-1R, sirtuin 1 (SIRT1), phospho-adenosine monophosphate-activated protein kinase (p-AMPK), phospho-acetyl-CoA carboxylase (p-ACC), and peroxisome proliferator-activated receptor alpha (PPARα) levels were analyzed using Western blotting.
Dulaglutide purchased from MedChemExpress. Usage Cited in: Endocrinol Metab. 2022 Feb;37(1):74-83. [Abstract]
Dulaglutide (Dula) inhibits lipid deposition and increases fatty acid oxidation via family with sequence similarity 3 member A (FAM3A). HepG2 cells transfected with 10 nM FAM3A small interfering RNA (siRNA) or control (Con) siRNA for 24 hours were pretreated with 400 μM palmitic acid (PA) for 24 hours, followed by treatment with or without 100 nM Dula for 24 hours. Lipid deposition was evaluated using triglyceride (TG) content assay.
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Chang W, et al. Glucagon-like peptide-1 receptor agonist dulaglutide prevents ox-LDL-induced adhesion of monocytes to human endothelial cells: An implication in the treatment of atherosclerosis. Mol Immunol. 2019 Dec;116:73-79. [Content Brief]
[2]. Hertzel C Gerstein, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet [Content Brief]
[3]. Byrd RA, et al. Chronic Toxicity and Carcinogenicity Studies of the Long-Acting GLP-1 Receptor AgonistDulaglutide in Rodents. Endocrinology. 2015 Jul;156(7):2417-28. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Dulaglutide 関連分類
HY-P0120 関連分類
Powered by Bioz